Last reviewed · How we verify
Immediate release torsemide
Immediate release torsemide is a Loop diuretic Small molecule drug developed by Sarfez Pharmaceuticals, Inc.. It is currently in Phase 2 development for Edema, Hypertension.
Inhibits the sodium-chloride cotransporter in the distal convoluted tubule of the kidneys.
Immediate release torsemide is a small molecule that inhibits the sodium-(potassium)-chloride cotransporter 2, which is a target of the solute carrier family 12 member 1. It is used to treat conditions such as congestive heart failure, chronic kidney diseases, hypertension, heart failure, and edema, as indicated by ClinicalTrials.gov.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Immediate release torsemide |
|---|---|
| Sponsor | Sarfez Pharmaceuticals, Inc. |
| Drug class | Loop diuretic |
| Target | Na-K-2Cl cotransporter 2 (NKCC2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
This leads to increased sodium and water excretion, resulting in a diuretic effect.
Approved indications
- Edema
- Hypertension
Common side effects
- Hypokalemia
- Hyponatremia
- Dehydration
Key clinical trials
- Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder (PHASE2)
- Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (PHASE4)
- Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects (PHASE3)
- A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs (PHASE4)
- Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal (PHASE2)
- Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects (PHASE1)
- Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immediate release torsemide CI brief — competitive landscape report
- Immediate release torsemide updates RSS · CI watch RSS
- Sarfez Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Immediate release torsemide
What is Immediate release torsemide?
How does Immediate release torsemide work?
What is Immediate release torsemide used for?
Who makes Immediate release torsemide?
What drug class is Immediate release torsemide in?
What development phase is Immediate release torsemide in?
What are the side effects of Immediate release torsemide?
What does Immediate release torsemide target?
Related
- Drug class: All Loop diuretic drugs
- Target: All drugs targeting Na-K-2Cl cotransporter 2 (NKCC2)
- Manufacturer: Sarfez Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Edema
- Indication: Drugs for Hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing